# 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

> **NCT07145177** · PHASE1 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **PROCEDURE:** Ablation
- **PROCEDURE:** Trans-arterial chemoembolization (TACE)
- **PROCEDURE:** Positron Emission Tomography (PET)/Computerized tomography (CT)
- **PROCEDURE:** Tumor Biopsy
- **OTHER:** Questionnaire

## Key facts

- **NCT ID:** NCT07145177
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2028-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145177, "177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07145177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*